1 / 1
Plozasiran API is a synthetic small interfering RNA (siRNA) developed for the treatment of hypertriglyceridemia and related cardiovascular and metabolic disorders. It targets the APOC3 gene, which encodes apolipoprotein C-III, a key regulator of triglyceride metabolism. In research, Plozasiran is used to study RNAi-based lipid-lowering strategies, gene-silencing specificity, and long-acting treatments for conditions such as familial chylomicronemia syndrome (FCS) and mixed dyslipidemia.
Plozasiran functions by silencing APOC3 mRNA in the liver, leading to a reduction in apolipoprotein C-III levels. This promotes enhanced lipolysis and clearance of triglyceride-rich lipoproteins from the bloodstream. As an API, Plozasiran enables the development of long-acting therapies aimed at significantly lowering triglyceride levels and reducing the risk of pancreatitis and cardiovascular events in patients with severe or genetic lipid disorders.
Plozasiran API is a synthetic small interfering RNA (siRNA) designed to target cardiovascular and metabolic disorders, specifically hypertriglyceridemia.
It targets the APOC3 gene, which encodes apolipoprotein C-III—a critical regulator of triglyceride metabolism in the human body.
It is utilized to research RNAi-based lipid-lowering mechanisms, gene-silencing specificity, and long-acting therapies for conditions like familial chylomicronemia syndrome (FCS) and mixed dyslipidemia.
It works by silencing APOC3 mRNA in the liver, which lowers apolipoprotein C-III levels and accelerates lipolysis and the clearance of triglyceride-rich lipoproteins.
By significantly reducing triglyceride levels, Plozasiran-based treatments aim to lower the risk of pancreatitis and cardiovascular events in patients with severe or genetic lipid disorders.
